Jarvis Sara S, Okada Yoshiyuki, Levine Benjamin D, Fu Qi
Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas, Dallas, Texas University of Texas Southwestern Medical Center, Dallas, Texas Department of Biological Sciences, Northern Arizona University, Flagstaff, Arizona.
Institute for Exercise and Environmental Medicine, Texas Health Presbyterian Hospital Dallas, Dallas, Texas University of Texas Southwestern Medical Center, Dallas, Texas.
Physiol Rep. 2015 Sep 14;3(9). doi: 10.14814/phy2.12502. Epub 2015 Sep 15.
Individuals with hypertension and sympathetic overactivity are at risk for cardiovascular events. Renin inhibitors are new while thiazide diuretics are first-class drugs used for treatment of hypertension. The purpose of this study was to determine whether 6 months of treatment with aliskiren (ALSK) or hydrochlorothiazide (HCTZ) would alter blood pressure (BP) and muscle sympathetic nerve activity (MSNA) indices in older mild hypertensives during a cold pressor test (CPT). We hypothesized that the ALSK group would demonstrate a blunted response compared to HCTZ. Nineteen (9 men, 10 women) subjects performed a CPT pre- and post treatment where heart rate (HR), systolic BP (SBP) and diastolic BP (DBP), and MSNA were measured. Blood samples were withdrawn for assessment of renal-adrenal hormones. Both medications lowered ambulatory SBP and DBP (P < 0.05). Direct renin tended to be higher in the ALSK group after treatment (P = 0.081). Aldosterone was higher in the HCTZ group after treatment (P < 0.001). As expected, both groups showed increases in HR, SBP, DBP, and MSNA during the CPT (all P < 0.05). All cardiovascular and MSNA responses were similar pre- and post treatment in both groups (peak CPT SBP: 26 ± 10 vs. 17 ± 21 and 21 ± 20 vs. 29 ± 15 mmHg for pre vs. post for HCTZ and ALSK, respectively; peak CPT MSNA burst frequency: 13 ± 8 vs. 11 ± 11 and 11 ± 17 vs. 6 ± 13 bursts/min; all P > 0.05). Treatment with these antihypertensive medications lowered BP but was not successful in lowering the responsiveness to the CPT.
高血压且交感神经活动亢进的个体有发生心血管事件的风险。肾素抑制剂是新药,而噻嗪类利尿剂是用于治疗高血压的一线药物。本研究的目的是确定阿利吉仑(ALSK)或氢氯噻嗪(HCTZ)治疗6个月是否会改变老年轻度高血压患者在冷加压试验(CPT)期间的血压(BP)和肌肉交感神经活动(MSNA)指标。我们假设与HCTZ组相比,ALSK组的反应会减弱。19名受试者(9名男性,10名女性)在治疗前后进行了CPT,测量了心率(HR)、收缩压(SBP)、舒张压(DBP)和MSNA。采集血样以评估肾-肾上腺激素。两种药物均降低了动态SBP和DBP(P<0.05)。治疗后ALSK组的直接肾素倾向于更高(P=0.081)。治疗后HCTZ组的醛固酮更高(P<0.001)。正如预期的那样,两组在CPT期间HR、SBP、DBP和MSNA均升高(所有P<0.05)。两组治疗前后所有心血管和MSNA反应均相似(HCTZ组CPT峰值SBP:治疗前vs治疗后分别为26±10 vs 17±21 mmHg,ALSK组为21±20 vs 29±15 mmHg;CPT峰值MSNA爆发频率:13±8 vs 11±11次/分钟和11±17 vs 6±13次/分钟;所有P>0.05)。这些抗高血压药物治疗可降低血压,但未能成功降低对CPT的反应性。